Barclays Initiates BioMarin Pharmaceutical With Overweight

By: via Benzinga
Analysts at Barclays initiated coverage on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) with a Overweight rating. The target price for ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.